Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assays
✍ Scribed by Louis P. Pertschuk; Joseph G. Feldman; Yong-Doo Kim; Lorraine Braithwaite; Frank Schneider; Albert S. Braverman; Constantine Axiotis
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 533 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND. Historically, estrogen receptor (ER) determinations have been made
by the ligand-binding assay of tumor homogenates, primarily by the dextrancoated charcoal method (DCC). Irnrnunocytochernical assays (ICA) for ER are more recent and have been executed mostly on frozen sections with the monoclonal antibody H222Spy (H222). Lately, new monoclonal antibodies derived by recombinant ER technology have been developed that work well on paraffin embedded, formalin fixed tissue sections. However, there is little information as to whether such assays prognosticate endocrine response.
METHODS. Using antigen retrieval, the immunoglobulin G, monoclonal antibody
ERlD5, and the streptavidin-biotin detection system, 74 patients with breast cancer in whom endocrine response was known were assayed and the results compared with ER by DCC and ER by ICA in frozen section with H222.